Report Overview

The UK Autoimmune Haemolytic Anaemia (AIHA) Therapeutics market size stood at around USD xx billion in 2020 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

AIHA is an autoimmune disorder characterised by the premature destruction of healthy red blood cells (RBCs) by auto-antibodies. It is a common disorder directed against self RBCs which can be idiopathic (primary) or secondary. In w-AIHA, the autoantibodies react optimally with the RBCs at 37C. Normally, red blood cells live in the body for 100 to 120 days. However, in severe cases of AIHA, the cells may remain only for a few days. In children, it is a rare condition that is usually temporary. In some adults, however, AIHA can be a long-term condition that returns frequently. AIHA can develop rapidly or over time.

AIHA is a decompensated acquired haemolysis caused by the host's immune system acting against its own red cell antigens. The incidence is 1 per 100,000/year and approximately half of the cases are secondary to an associated disorder. Serologically, cases are divided into warm, cold (cold haemagglutinin disease and paroxysmal cold haemoglobinuria) or mixed AIHA.



Market Growth Drivers

The AIHA market is primarily driven by an increase in the use of drugs, such as corticosteroids, for patients with autoimmune haemolytic anaemia. The prevalence of AIHA is rising due to the rapidly increasing geriatric population. The geriatric population is more vulnerable to diseases due to poor immunity, hence fosters market growth.

The steady increase in the use of immunoglobulin for the treatment of off-label indications is expected to drive the market during the forecast period. Technological improvements in the production and purification methods of intravenous immunoglobulins (IVIG) have made these safer and free from protein, viral, or any other contaminants. This has increased clinician preference for the usage of IVIG. This, in turn, boosts the market growth during the forecast period.

The cost of plasma collection and manufacturing processes is high as compared to materials and processes used in the manufacture of traditional pharmaceutical products. Moreover, being a blood-derived component, highly sophisticated collection, purification, and storage methods are required for IVIG products.

Market Restraints

Due to fewer market players and the time gap between plasma collection and getting the product in the market, IVIG production becomes a tedious and time-consuming process, if not managed properly can hamper the IVIG, thus, in turn, the IVIG market during the forecast period.